Mantle Cell Lymphoma, bcl-1/JH t(11;14), FISH, Blood
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma (NHL). Mantel cell lymphoma is a fast-growing high-grade lymphoma. Diagnosis of mantle cell lymphoma is typically made in patients with a mean age of 60 and is more common in men. Enlarged lymph nodes are the most common symptom, usually in the neck, groin, and underarm. Since it is fast growing, it may involve the spleen, bone marrow, and throat. Occasionally the disease can involve the intestines, causing abdominal pain and diarrhea. Diagnosis of mantle cell lymphoma is similar to the diagnosis of other lymphomas: tissue biopsy with pathologic examination, bone marrow exam, blood tests and scans. Disease staging is made after all the tests and scans are done.
Most people are diagnosed after the disease involves multiple areas of the body, which is typically stage III or IV. Treatment is typically by chemotherapy and limited use of radiation therapy. Genetically, mantle cell lymphoma is classified as a B-Cell Lymphoma and typically has a mutation of the t(11:14)(q13;q32) translocation, and deletions of the ATM gene are typical. The t(11;14)(q13;q32) translocation causes deregulation of the bcl-1 gene and over-expression of cyclin D1, which may in turn lead to lymphoma genesis. The bcl-1 translocation is specific for mantle cell lymphoma and occurs in the majority of cases. Detection of the bcl-1/JH gene rearrangement [t(11;14)(q13;q32)] can be helpful in the differential diagnosis of mantle cell lymphoma and in following up patients during and after treatment. Using the mutation information, physicians can better predict disease progression and prescribe treatment.
- Diagnose mantle cell lymphoma
- Assess the effectiveness of therapy
- Monitor minimal residual disease (MRD)
- Predict early relapse
If there is no BCL-1 amplification (BCL-1:Ki-Ras ratio = 0), the result is reported as negative. If there is amplification of BCL-1, the result is positive and the ratio is reported.
A positive result indicates the presence of the BCL-1 t(11;14) translocation characteristic of mantle cell lymphoma. Because this translocation occurs in only about two-thirds of cases, a negative result does not preclude the diagnosis of mantle cell lymphoma. The results should be interpreted in the context of other clinical and pathologic features.
To monitor MRD, we recommend evaluating changes with time (trend) rather than the absolute ratio from a single measurement.
Negative (No translocation detected)
Fluorescence in situ hybridization (FISH).
Whole Blood ACD (Yellow), EDTA (Lavender) & Bone Marrow.
Stability
- Ambient: 7 days
- Refrigerated: 14 days
Tissue
Stability
- Ambient: 12 months
- Refrigerated: 12 months
- Histopathology. 1999 Mar;34(3):266-70. [PMID: 10217569]
- J Clin Oncol. 2005 Sep 10;23(26):6364-9. [PMID: 16155021]
- Br J Haematol. 2008 Jun;142(2):149-65. [PMID: 18410453]
- Blood Rev. 2009 Sep;23(5):205-16. [PMID: 19362399]
- Nat Rev Cancer. 2007 Oct;7(10):750-62. [PMID: 17891190]